BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37204099)

  • 1. Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).
    Hada N; Katsume A; Kenichi K; Endo C; Horiba N; Sudoh M
    Pharmacol Res Perspect; 2023 Jun; 11(3):e01094. PubMed ID: 37204099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
    Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
    Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
    Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice.
    Majeed M; Majeed S; Nagabhushanam K; Lawrence L; Mundkur L
    Sci Rep; 2020 May; 10(1):7440. PubMed ID: 32366854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Role of Stellate Cell VCAM-1 in NASH Models in Mice.
    Chung KJ; Legaki AI; Papadopoulos G; Gercken B; Gebler J; Schwabe RF; Chavakis T; Chatzigeorgiou A
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.
    Wang W; Zhao C; Zhou J; Zhen Z; Wang Y; Shen C
    PLoS One; 2013; 8(10):e76538. PubMed ID: 24098525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
    Kimura T; Singh S; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
    Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
    Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
    Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
    Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
    Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
    Nguyen G; Park SY; Le CT; Park WS; Choi DH; Cho EH
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2649-2656. PubMed ID: 29278707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-552-3p Regulates Multiple Fibrotic and Inflammatory genes Concurrently in Hepatic Stellate Cells Improving NASH-associated Phenotypes.
    Ma N; Hou A; Pan X; Sun F; Xu X; Yu C; Lai R; Huang R; Gong L; Xie Q; Chen J; Ren J
    Int J Biol Sci; 2023; 19(11):3456-3471. PubMed ID: 37496991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
    Segal-Salto M; Barashi N; Katav A; Edelshtein V; Aharon A; Hashmueli S; George J; Maor Y; Pinzani M; Haberman D; Hall A; Friedman S; Mor A
    JHEP Rep; 2020 Feb; 2(1):100064. PubMed ID: 32039405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.